Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (Xa), thereby inhibiting coagulation.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
IV infusion: Initial bolus 80 units/kg, then continuous infusion at 18 units/kg/hr. Adjust based on aPTT. Subcutaneous: 5,000-10,000 units every 8-12 hours.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
1.5 hours (dose-dependent and increases with higher doses; e.g., 2.5 hours after 25,000 units IV; prolonged in hepatic or renal impairment)
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Renal (clearance primarily via reticuloendothelial system and liver, with minimal renal excretion of intact heparin; metabolites eliminated renally; <5% excreted unchanged in urine)
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte